Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 427

1.

[Interventional therapy of heart valve diseases : Future perspectives].

Figulla HR, Lauten A.

Herz. 2015 Apr;40(2):215-23. doi: 10.1007/s00059-015-4207-5. German.

PMID:
25822420
2.

Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial.

Thiele H, Schuler G, Neumann FJ, Hausleiter J, Olbrich HG, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de Waha S, Eitel I, Hambrecht R, Böhm M, Kurowski V, Lauer B, Minden HH, Figulla HR, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SK, Möllmann H, Schneider S, Ebelt H, Werdan K, Zeymer U; IABP-SHOCK II Trial Investigators.

Am Heart J. 2015 Apr;169(4):e7-8. doi: 10.1016/j.ahj.2015.01.009. Epub 2015 Jan 30. No abstract available.

PMID:
25819870
3.

Investigation of bacterial translocation in chronic ischemic heart failure in the rat.

Betge S, Stingl M, Pfister W, Figulla HR, Jung C.

Clin Lab. 2015;61(1-2):93-100.

PMID:
25807643
4.

QT variability improves risk stratification in patients with dilated cardiomyopathy.

Fischer C, Seeck A, Schroeder R, Goernig M, Schirdewan A, Figulla HR, Baumert M, Voss A.

Physiol Meas. 2015 Apr;36(4):699-713. doi: 10.1088/0967-3334/36/4/699. Epub 2015 Mar 23.

PMID:
25799313
5.

Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy.

Jung C, Fuernau G, de Waha S, Eitel I, Desch S, Schuler G, Figulla HR, Thiele H.

Clin Res Cardiol. 2015 Feb 27. [Epub ahead of print]

PMID:
25720332
6.

Elevated plasma levels of interleukin-12p40 and interleukin-16 in overweight adolescents.

Lichtenauer M, Franz M, Fritzenwanger M, Figulla HR, Gerdes N, Jung C.

Biomed Res Int. 2015;2015:940910. doi: 10.1155/2015/940910. Epub 2015 Feb 2.

7.

Impairment of the endothelial glycocalyx in cardiogenic shock and its prognostic relevance.

Jung C, Fuernau G, Muench P, Desch S, Eitel I, Schuler G, Adams V, Figulla HR, Thiele H.

Shock. 2015 May;43(5):450-5. doi: 10.1097/SHK.0000000000000329.

PMID:
25692257
8.

Decreased regulatory T cells in vulnerable atherosclerotic lesions: imbalance between pro- and anti-inflammatory cells in atherosclerosis.

Rohm I, Atiskova Y, Drobnik S, Fritzenwanger M, Kretzschmar D, Pistulli R, Zanow J, Krönert T, Mall G, Figulla HR, Yilmaz A.

Mediators Inflamm. 2015;2015:364710. doi: 10.1155/2015/364710. Epub 2015 Jan 15.

9.

Percutaneous extracorporeal life support in patients with circulatory failure: results of the German Lifebridge Registry.

Jung C, Franz M, Figulla HR, Sonntag S, Hug M, Mudra H, Bauerschmitt R, Kleber FX, Feindt P, Mehlhorn U, Vahl C, Bruns HJ, Ferrari M.

J Invasive Cardiol. 2015 Feb;27(2):93-7.

10.

Decrease in circulating plasmacytoid dendritic cells during short-term systemic normobaric hypoxia.

Yilmaz A, Ratka J, Rohm I, Pistulli R, Goebel B, Asadi Y, Petri A, Kiehntopf M, Figulla HR, Jung C.

Eur J Clin Invest. 2015 Feb 4. doi: 10.1111/eci.12416. [Epub ahead of print]

PMID:
25652640
11.

Comparison of outcomes of patients with left ventricular ejection fractions ≤30% versus ≥30% having transcatheter aortic valve implantation (from the German Transcatheter Aortic Valve Interventions Registry).

Schaefer U, Zahn R, Abdel-Wahab M, Gerckens U, Linke A, Schneider S, Eggebrecht H, Sievert H, Figulla HR, Senges J, Kuck KH; German TAVI Registry.

Am J Cardiol. 2015 Mar 1;115(5):656-63. doi: 10.1016/j.amjcard.2014.12.019. Epub 2014 Dec 18.

PMID:
25613664
12.

Toxic Epidermal Necrolysis During Dronedarone Treatment: First Report of a Severe Serious Adverse Event Of A New Antiarrhythmic Drug.

Gecks T, Prochnau D, Franz M, Jung C, Kühnert H, Schliemann S, Figulla HR.

Cardiovasc Toxicol. 2015 Jan 15. [Epub ahead of print]

PMID:
25588686
13.

Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Franz M, Jung C, Lauten A, Figulla HR, Berndt A.

Cell Adh Migr. 2015 Jan 2;9(1-2):90-5. doi: 10.1080/19336918.2014.1000075.

PMID:
25562641
15.

Resistant hypertension: four years of follow-up of an unusual course after renal denervation in a patient with end stage renal disease.

Prochnau D, Figulla HR, Surber R.

Int J Cardiol. 2015 Feb 1;180:86-7. doi: 10.1016/j.ijcard.2014.11.170. Epub 2014 Nov 25. No abstract available.

PMID:
25438222
16.

TAVI for low-flow, low-gradient severe aortic stenosis with preserved or reduced ejection fraction: a subgroup analysis from the German Aortic Valve Registry (GARY).

Lauten A, Figulla HR, Möllmann H, Holzhey D, Kötting J, Beckmann A, Veit C, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler G, Walther T, Beyersdorf F, Böhm M, Heusch G, Meinertz T, Neumann T, Welz A, Mohr FW, Hamm CW; GARY Executive Board.

EuroIntervention. 2014 Nov;10(7):850-9. doi: 10.4244/EIJV10I7A145.

PMID:
25415152
17.

Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.

Poerner TC, Otto S, Gassdorf J, Nitsche K, Janiak F, Scheller B, Goebel B, Jung C, Figulla HR.

Circ Cardiovasc Interv. 2014 Dec;7(6):760-7. doi: 10.1161/CIRCINTERVENTIONS.113.001146. Epub 2014 Nov 4.

PMID:
25371536
18.

Simulated temporary hypoxia triggers the release of CD31+/Annexin+ endothelial microparticles: A prospective pilot study in humans.

Lichtenauer M, Goebel B, Fritzenwanger M, Förster M, Betge S, Lauten A, Figulla HR, Jung C.

Clin Hemorheol Microcirc. 2014 Oct 16. [Epub ahead of print]

PMID:
25322787
19.

Optimal prosthesis sizing in transcatheter aortic valve implantation by exclusive use of three-dimensional transoesophageal echocardiography.

Kretzschmar D, Lauten A, Goebel B, Doenst T, Poerner TC, Ferrari M, Figulla HR, Hamadanchi A.

Clin Physiol Funct Imaging. 2014 Oct 15. doi: 10.1111/cpf.12200. [Epub ahead of print]

PMID:
25316588
20.

Renal denervation with cryoenergy as second-line option is effective in the treatment of resistant hypertension in non-responders to radiofrequency ablation.

Prochnau D, Heymel S, Otto S, Figulla HR, Surber R.

EuroIntervention. 2014 Sep;10(5):640-5. doi: 10.4244/EIJV10I5A110.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk